ARTICLE | Finance

D is for data

Celator gets $20M D round based on Phase II leukemia data

September 6, 2010 7:00 AM UTC

Alex Zisson, a partner at Thomas, McNerney & Partners, has been following the liposome space since his research analyst days at Hambrecht & Quist, and has watched Celator Pharmaceuticals Inc. in particular over the last few years.

Following positive Phase II data reported in May for Celator's lead candidate CPX-351 to treat acute myelogenous leukemia (AML), Thomas McNerney opted to lead last week's $20 million series D round as a new investor...